Willow Biosciences Inc announced the results of its in-vitro analysis and the first to be reported topical clinical study on cannabigerol (CBG).
The Vancouver, British Columbia-based company said that a single-blind clinical study in 20 healthy male and female volunteers conducted at Princeton Consumer Research showed Willow's FutureGrown CBG clinically reduces skin inflammation, the appearance of redness, and improves barrier function.
READ: Willow Biosciences closes 3Q with $35.7M in cash while making notable advancements in its operations
"Willow's FutureGrown CBG continues to exhibit great promise as an exciting new skincare ingredient", said Trevor Peters, Willow's CEO in a statement. "We are excited to share the results of our in vitro and clinical work with our stakeholders and proud to have it published in a peer-reviewed scientific journal, the first of its kind for CBG.”
Peters noted that as the market for CBG and CBGA continues to develop, key studies such as the company’s help to define the potential these ingredients have in the health and wellness space.
In collaboration with Signum Biosciences, Willow's FutureGrown CBG, produced using its proprietary yeast platform at a multi-kilogram scale, demonstrated antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays, and provided similar benefits when applied topically to human skin, the company said.
The results of the Willow study were published in Molecules, a leading international, peer-reviewed, open-access journal that can be found HERE.
The Willow study reported that biosynthetically produced CBG possesses a broad range of anti-inflammatory, antioxidant, and skin-protecting properties to help slow inflammation, aging, and boost skin barrier function.
Gene array analysis of CBG and cannabidiol (CBD) applied topically to a 3D human skin model demonstrates that CBG outperforms CBD, selectively targeting collagen, elastin, and other key skin health and hydration genes.
Moreover, in vitro studies in normal human epidermal keratinocytes (NHEKs) and human dermal fibroblasts (HDFs) show that CBG and CBD both possess strong antioxidant and anti-inflammatory properties, with CBG demonstrating equal if not better activity than CBD.
Lastly, the Willow study is the first to report the clinical effectiveness of topically applied CBG, demonstrating that a 0.1% CBG serum reduces inflammation, redness, and improves the skin barrier significantly better than a placebo.
Contact Ritika at ritika@proactiveinvestors.com